<DOC>
	<DOCNO>NCT00433498</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , etoposide , cisplatin , carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Pravastatin may stop growth tumor cell block enzymes need cell growth make tumor cell sensitive chemotherapy . It yet know whether etoposide cisplatin carboplatin effective without pravastatin treat small cell lung cancer . PURPOSE : This randomized phase III trial study etoposide cisplatin carboplatin see well work give first-line chemotherapy together pravastatin compare first-line chemotherapy placebo treat patient small cell lung cancer .</brief_summary>
	<brief_title>Etoposide Cisplatin Carboplatin First-Line Chemotherapy With Without Pravastatin Treating Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient small cell lung cancer treat etoposide phosphate combination cisplatin carboplatin first-line chemotherapy v without pravastatin . Secondary - Compare progression-free survival patient treat regimen . - Compare local progression-free survival ( local control ) patient . - Compare response rate patient . - Compare toxicity regimens patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord disease stage ( limited stage v extensive stage ) , ECOG performance status ( 0 1 v 2 3 ) , participate site . Patients randomize 1 2 treatment arm . All patient receive chemotherapy comprise cisplatin IV carboplatin IV day 1 etoposide phosphate IV day 1-3 orally twice daily day 2 3 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm I : Patients receive oral pravastatin daily begin day 1 chemotherapy continue 24 month . - Arm II : Patients receive oral placebo daily begin day 1 chemotherapy continue 24 month . Some patient may undergo blood urine sample collection baseline periodically study treatment . Samples examine genetic analysis , metabonomics proteomics ( detect expression RAS proteins , phospho-Erk , signal downstream RAS ) , cholesterol measurement . After completion study treatment , patient follow every 2 month 1 year every 3 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK . PROJECTED ACCRUAL : A total 842 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Limited stage extensive stage disease No mixed cell histology No symptomatic brain metastasis require immediate radiotherapy PATIENT CHARACTERISTICS : ECOG performance status 03 Life expectancy &gt; 8 week Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count &gt; 1,500/mm^3 Glomerular filtration rate ≥ 50 mL/min Creatine kinase ≤ 5 time upper limit normal ( ULN ) Liver function test ( ALP , ALT/AST , bilirubin ) &lt; 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 year completion chemotherapy/radiotherapy additional 28 day completion pravastatin sodium Able tolerate chemotherapy No evidence significant medical condition laboratory finding , opinion investigator , would preclude study participation No family history hypercholesterolemia No history malignant tumor unless patient without evidence disease ≥ 3 year tumor nonmelanoma skin tumor early cervical cancer PRIOR CONCURRENT THERAPY : More 12 month since prior statin More 4 week since prior fibrates ( e.g. , bezofibrate , gemfibrozil , fenofibrate ) No prior chemotherapy cancer No prior radiotherapy cancer unless distant metastasis ( i.e. , within thorax thoracic/cervical spine area ) No concurrent cyclosporine Concurrent radiotherapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>